Aegerion To Pay Investors $22M In Juxtapid Marketing Row
Aegerion Pharmaceuticals Inc. on Monday said it has agreed to pay $22.25 million to settle an investor class action in Massachusetts federal court alleging the biopharmaceutical company misled shareholders about off-label...To view the full article, register now.
Already a subscriber? Click here to view full article